Our Common Path to Success

Our partnering model is based on our full understanding of your antibody drug development challenge. Upon successful validation of your target and reporter cell system for our platform, we start to elaborate a workplan with deliverables and in addition a draft term sheet for the next project steps which then would lead to the following collaboration models:

  • Research & License Option Agreement
  • Technology License Agreement
  • Co-Ownership Agreement

VERAXA’s technology has been successfully validated in various industry and academic collaborations. Over the last years, VERAXA has successfully gathered an unmet know how for the performance of quantitative functional antibody screens on GPCRs and other very complex membrane bound receptors.

Our approach to tackle your antibody challenge

We are typically screening up to 250.000 B-cells within 8 h on one single workstation, either in antagonizing or agonizing setups. Due to easy parallelization, we can screen 1 to 2 million B-cells in a few days. Typical hit rates may vary between 1 in 2.000 and 1 in 10.000 B-cells leading in general to about 30 to 130 positively sorted out hits per single 8 h screen. Variations in stringency of the filtering functional gates may increase or decrease this numbers. In general, we can find several hundred up to more than 1.000 hits per total screening campaign which then will be used for further sequencing and validation studies.

STEP 0: Kick-off

You deliver:

  • Stable target receptor over expressing cell line(s) (reporter cells for screening)
  • Target expressing cell lines and target receptor protein (for immunization), if needed
  • Control substances (agonists, antagonists)

STEP 1: Feasibility

We do:

  • Analyze material completeness and suitability
  • Optimize S/N of receptor signaling associated fluorescence on FACS and plate

You get:

  • Transposition of setup on our microfluidic systems and S/N optimization
  • Work out of Research Plan
  • Termsheet proposition

STEP 2: Immunization

We do:

  • Work out of jointly approved immunization protocol
  • Start immunization

You get:

  • Harvesting of tissues and B-cell extraction

STEP 3: Screening

We do:

  • Perform B-cell screening

You get:

  • Sorting and sampling of B-cell hits

STEP 4: Sequencing

We do:

  • NGS-based single cell sequencing of B-cell hits

You get:

  • Delivery of antibody hit sequences

STEP 5: Synthesis

If needed:

  • Antibody synthesis and further validation